A former drug discovery firm with just $130,000 in recent annual revenue has secured an AI infrastructure contract worth 2,000 times that figure, sending its stock into the stratosphere.
Back
A former drug discovery firm with just $130,000 in recent annual revenue has secured an AI infrastructure contract worth 2,000 times that figure, sending its stock into the stratosphere.

Axe Compute Inc. (NASDAQ:AGPU), a company that pivoted from drug discovery to AI just four months ago, saw its shares surge over 100% after announcing a $260 million, three-year deal to provide a dedicated AI infrastructure cluster. The agreement, supported by Aethir's decentralized cloud infrastructure, represents a monumental leap for the micro-cap firm and signals a growing enterprise appetite for alternatives to established hyperscale providers like Amazon Web Services and Microsoft Azure.
"This agreement is a signal. Enterprise AI customers are no longer willing to adapt their infrastructure roadmaps to the capacity constraints of legacy hyperscalers," Christopher Miglino, Chief Executive Officer of Axe Compute, said in a statement. "A 2,304-GPU B300 deployment, contracted, dedicated, U.S.-based, and priced to compete, is what purpose-built AI infrastructure looks like."
Under the 36-month contract, Axe Compute will deploy 2,304 of Nvidia’s (NASDAQ:NVDA) powerful B300 GPUs for a single enterprise client in a U.S.-based Tier 3 data center. The deployment, scheduled to begin in the third quarter of 2026, includes 4.8 megawatts of dedicated power and is structured as a take-or-pay agreement, providing a predictable revenue stream for a company that posted a GAAP loss of $13.37 per share in its last fiscal year.
The deal sent investors into a frenzy, catapulting the stock to a valuation of more than 200 times its trailing sales. While the contract offers a lifeline and significant validation, Axe Compute remains a high-risk penny stock with no Wall Street coverage, facing substantial execution hurdles and questions about its now-elevated valuation.
The landmark contract provides crucial validation for Axe Compute's abrupt strategy shift. Formerly Predictive Oncology, the company changed its name and business model in late 2025 to focus on high-performance AI infrastructure. By securing thousands of Nvidia’s latest Blackwell-generation GPUs, the Nasdaq-listed firm has forcefully entered the competitive high-performance computing market.
The deal’s structure is as important as its size. The take-or-pay basis with a deposit and monthly advance payments offers a predictable, recurring revenue stream—a feature historically absent from Axe Compute’s finances. The involvement of Aethir's decentralized physical infrastructure network (DePIN) also points to a broader industry trend, suggesting enterprise clients are exploring novel infrastructure models to gain flexibility and bypass the supply constraints often encountered with major cloud providers.
Despite the euphoria that drove the stock’s 14-day relative strength index (RSI) into the mid-80s—a technical sign of overbought conditions—significant risks loom. Axe Compute has the characteristics of a high-risk penny stock, making it vulnerable to extreme volatility. The absence of coverage from Wall Street analysts means there are no independent financial models or price targets to anchor valuation.
At a price-to-sales (P/S) ratio exceeding 200x, the company's valuation is stretched, pricing in flawless execution of this contract and the successful acquisition of many more like it. However, the $260 million deal doesn’t begin deployment until the third quarter, meaning Axe Compute must survive another two quarters of high cash burn before revenue begins to flow. This raises the risk of further share dilution if the company needs to raise capital to bridge the gap. While the deal is a clear win, investors are now weighing whether this single contract is enough to justify the company's new multi-million dollar market capitalization.
This article is for informational purposes only and does not constitute investment advice.